ABUS (Arbutus Biopharma Corp) Bathi saben saham sajrone rolas wulan pungkasan

Logo perusahaan publik Arbutus (ABUS)

Arbutus Biopharma relies on stable demand within the biotech sector, establishing it as a defensive asset regardless of macroeconomic conditions. The robotization of RNA interference testing accelerates formula discovery, freeing staff from routine tasks. The Hepatitis B cure strategy is based on LNP technologies. The year-over-year EPS dynamics (over 12 months) on this GURU.Markets chart shows that 608.30 reflects the most recent value of the metric.

arbutusbio.com (ABUS): Bathi saben saham sajrone rolas wulan pungkasan saka 11.02.2024 nganti 17.11.2026

ABUS (Arbutus Biopharma): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
Pambiji fundamental perusahaan:Arbutus - ABUS
Produk seri Tekmira Pharmaceuticals

The development of hepatitis B therapy and the outcome of the patent dispute with Moderna determine the financial stability of Arbutus Biopharma (ABUS). An analysis of the EPS YoY TTM shift, reflecting the daily growth rate of earnings per share over the year, allows for an assessment of the real return on capital and the company's ability to service its obligations amid rising interest rates, confirming the business's viability even amidst the risk of compressing market multiples.